Casdatifan (cas) is an investigational small molecule inhibitor of HIF-2⍺, a transcription factor that upregulates hundreds of oncogenic genes in a hypoxic environment. By selectively binding HIF-2⍺, casdatifan is designed to disable a wide array of tumor growth and survival pathways, leading to cancer cell death.
Quemliclustat (quemli) is an investigational small molecule that inhibits CD73, a major enzymatic producer of immunosuppresive adenosine. By blocking CD73 production of adenosine, quemliclustat is designed to prevent adenosine suppression, which unleashes immune cells to trigger cancer cell death.
Zimberelimab (zim) is a monoclonal antibody that binds PD-1, a well-established checkpoint of anti-cancer immunity. Gloria Biosciences received approval for zimberelimab in China for classical Hodgkin lymphoma and recurrent/metastatic cervical cancer.
